Sheet 1 of 1

FORM PTO-1449		US Dept. Of Commerce Patent and Trace HAD Office		ATTORNEY DOCKET NO.		SERIAL NO.			
ratent and That entrary Office				4121-122		09/834,291	09/834 291		
				APPLICANT		HE(CFIVE		
NFORM	ATION D	DISCLOSURE ST	FATEMENT	IVD AND CODE				- ' V [
(use several sheets if necessary)				KRAMMER, et al. FILING DATE	09/834,291 RECEIVE MAY 2 9 200 GROUP TECH CENTER 1600				
	(use seve	iai sileets ii liece	ssary)	FILING DATE	GROUP				
				April 12, 2001		1646	CH CEN	TER 1600	
			U.S.	PATENT DOCUMENTS	8				
EXAMINE R INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
			FOREI	CN DATERIT DOCUMEN	VITO.				
	T	DOCUMENT	PUBLICATION	GN PATENT DOCUMEN	VIS		TRANS	LATION	
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO	
2.	AA	WO 98/08965	5 March 1998	PCT			-		
NS	AB	0 518 650	10 June 1992	Europe					
00	AC	WO 95/19367	20 July 1995	PCT					
		OTHER DOCL	MENTS (Includ	ling Author Title Journa	L-Date Page N	lumber Etc.)			
DR	AD-	OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) Behrmann, et al., "Structure of the human APO-1 gene." Eur. J. Immunol. 1994. 24: p. 3057-3062.							
05	AE J	XP 000572417. Chan & Owen Schaub, "Identification and analysis of A p53 binding element within the promoter of the FAS/APO-1 (CD95) gene,"							
DR	AF	XP-000906792. Muller et al., "p53 activates the CD95 (APO-1/FAS) gene in response to DNA damage by anticancer drugs," J. Exp. Med. 1998: Vol. 188, No. 11. p. 2033-2045.							
Ŋ	AG	XP-000906826. Rudert et al., "Identification of a silencer, enhancer, and basal promoter region in the human CD95 (FAS/APO-1) gene," DNA and Cell Biol., 1995: Vol. 14, No. 11, p. 931-937.							
XAMINI	ER .				DATECO	MSIDEDED			
XAMINI		edu	···		DATE CO	ONSIDERED			